Advancing green chemistry for more sustainable medicines
By applying the principles of eco-design and green chemistry, we developed an innovative manufacturing process with reduced environmental footprint.
Search
Veterinary oncology - cancer treatment
Our R&D team's efforts toward finding new cancer treatments for pets
Boehringer Ingelheim attends WVPAC 2019
Boehringer Ingelheim attends and showcases its leading vaccines and services at 21st World Veterinary Poultry Association Congress
Boehringer Ingelheim becomes member of IPC
Boehringer Ingelheim becomes member of IPC Boehringer Ingelheim is proud to join the International Poultry Council thus reaffirming its strong long-term commitment to shaping the future of poultry health. The International Poultry Council represents a uni
LastMile – improving through digital
LastMile initiative is an integrated, solutions-driven program seeking to make animal medical resources available in hard-to-reach areas in Africa.
Big Little Things in cancer: small things, big impacts
Little things can be a big deal when you are living with or treating cancer. Sometimes the small things are the most powerful.
New cancer research building: Boosting innovation in oncology
With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
EASi-KIDNEY™ Phase III trial for people with CKD
Boehringer Ingelheim's Sandy Sommer on how treatment innovations in CKD can also improve care for connected conditions, including heart failure.
New African Swine Fever Manual published
Boehringer Ingelheim joined forces with the leading veterinarians to fight African swine fever. The new African Swine Fever Knowledge Handbook published.
Boehringer upgrade in Access to Medicine Health Ranking
Boehringer’s focus on Health Equity drives significant upgrade in Access to Medicine Index Ranking
Fast-Track-Designation-NASH
Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
Advance study vaccinating increased milk production
[New ADVANCE study shows vaccinating with Bovela® results in increased milk production
12th Expert Forum on Farm Animal Well-Being
The 12th Expert Forum on Farm Animal Well-Being brought together over 100 industry experts
Social Media Data Privacy and Cookies Statement
Circular economy: Taking action to reduce plastic waste
The packaging department team at Yamagata, Japan, managed to reduce their waste plastic material for a greener and more sustainable tomorrow
Our culture
Our culture reflects who we are and is reflected in Our FOCUS and strong belief in Diversity, Equity and Inclusion as well as Sustainable Development.
Phase II trial results in people living with obesity or overweight
Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas
Growing with us
We recognize the benefits of learning and have created an environment where life-long learning and personal growth are encouraged for all employees.
Heidelberg Innovation Prize
Apply for the Heidelberg Innovation Prize – an award given to young life-science companies taking discovery to the next level.
InSensitive Content: the impact on dermatologists
Learn about the importance of the dermatology community sharing content related to generalized pustular psoriasis on social media.
New indications NexGard, NexGard SPECTRA and Broadline
New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA
Rabies? Not in Mexico!
Mexico has been a rabies-free country for the last five years. How does Mexico achieve this? Learn how we're collaborating in this fight against rabies.